DD2 - Danish Centre for Strategic Research in Type 2 Diabetes

Advancing type 2 diabetes research through the DD2 cohort

On November 21, 2025, the DD2 Research Symposium will showcase the latest scientific advances made possible through the unique DD2 cohort. The symposium highlights both new initiatives and ongoing studies, offering a forum for knowledge exchange and collaboration across disciplines in diabetes research. 

The target audience includes researchers already working on DD2, those planning to initiate DD2 projects, and others interested in leveraging the cohort for future studies.

A key feature of the day is the introduction of five newly awarded research projects funded by the Novo Nordisk Foundation. These studies will leverage DD2 data and biobank resources to address critical questions in type 2 diabetes:

• DD2-PRÆCIS, led by Associate Professor Jordi Merino, aims to uncover hidden patterns in treatment response.

• DIAGMENT, led by Postdoc Sara Stinson, focuses on improving risk profiling for diabetes complications.

• REST-DD2, led by Postdoc Thomas Bastholm Olesen, investigates the causes of nocturnal breathing disturbances.

• DNA methylation, led by Professor Charlotte Ling, explores epigenetic biomarkers to predict treatment response.

• CysDD2, led by Postdoc Morten Baltzer Houlind, tests new kidney function biomarkers to enhance diagnosis and treatment.

In addition, ongoing and completed DD2-based studies will be presented, covering themes such as genetic risk, cardiovascular outcomes, inflammation, and digital treatment strategies. The program concludes with a keynote lecture on sleep and type 2 diabetes by Professor Poul Jørgen Jennum, followed by an open discussion on new project ideas and collaborations.

By bringing together leading researchers and fostering dialogue, the DD2 Research Symposium continues to strengthen the use of the DD2 cohort as a cornerstone for advancing precision medicine in type 2 diabetes.